US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma

Date: April 22, 2011
Pages: 28
Price:
US$ 2,999.00 US$ 500.00
License [?]:
Publisher: The Assessment Group
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U07A2FEB2CFEN
Leaflet:

Download PDF Leaflet

US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma
Patient specific case scenario on advanced non-Hodgkin’s lymphoma in a situation involving a patient with Stage IIIA Asymptomatic Indolent Lymphoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:
  • Decisions in treatment and tests through disease stages
  • Factors influencing their decisions
  • Barriers to optimal patient care
  • Confidence in treatment

Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on advanced non-Hodgkin’s lymphoma.

Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:
  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
  • Design messages to advance brand performance
EXECUTIVE SUMMARY

CHAPTER 1: INTRODUCTION

Table 1. Treatment Options in Non-Hodgkin’s Lymphoma

CHAPTER 2: RESPONDENT DEMOGRAPHICS

Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.6 Survey Respondents by State’s Non-Hodgkin’s Lymphoma Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

CHAPTER 3: TREATMENT OF STAGE IIIA ASYMPTOMATIC INDOLENT LYMPHOMA

Figure 3.1 Initial treatment of asymptomatic indolent lymphoma
Figure 3.2 Treatment goals for this patient
Figure 3.3 Confidence in management of this patient
Figure 3.4 Most important barriers to optimal treatment
Figure 3.5 Treatment upon disease progression
Figure 3.6 Treatment on further disease progression
Figure 3.7 Factors influencing treatment

CHAPTER 4. SUMMARY

Appendix A: Survey Instrument
Skip to top


Ask Your Question

US Oncologist Survey: Optimizing Treatment for Stage IIIA Asymptomatic Indolent Lymphoma
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: